<DOC>
	<DOCNO>NCT02007720</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability intravenous infusion serelaxin , add standard therapy , acute heart failure ( AHF ) patient .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Sexelaxin When Added Standard Therapy AHF</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Male female ≥ 18 year age , body weight ≤160 kg Hospitalized AHF ; AHF define include follow measured time presentation ( include emergency department outpatient clinic ) end screening : Persistent dyspnea rest minimal exertion screen time randomization Pulmonary congestion chest radiograph Brain natriuretic peptide ( BNP ) ≥500 pg/mL NTproBNP ≥2,000 pg/mL Systolic BP ≥125 mmHg start end screen Able randomize within 16 hour presentation hospital , include emergency department outpatient clinic Received intravenous furosemide least 40 mg total ( equivalent ) time presentation ( include outpatient clinic , ambulance , hospital include emergency department ) start screen study treatment current acute HF episode Renal impairment define estimate glomerular filtration rate use presentation randomization ≥ 25 ≤75mL/min/1.73m2 , calculate use Modification Diet Renal Disease formula ( modify sMDRD formula accord specific ethnic group local practice guideline ) . Dyspnea primarily due noncardiac cause Temperature &gt; 38.5°C ( oral equivalent ) , sepsis , active clinically significant infection require IV antimicrobial treatment know presence evidence Human Immunodeficiency Virus ( HIV ) infection ( base history and/or clinical finding , include laboratory result obtain screening period ) . Clinical evidence acute coronary syndrome currently within 30 day prior enrollment *Patients systolic blood pressure &gt; 180 mmHg end screen AHF due significant arrhythmia , include follow : sustain ventricular tachycardia , bradycardia sustain ventricular rate &lt; 45 beat per minute , atrial fibrillation/flutter sustain ventricular response &gt; 130 beat per minute Hepatic disease unrelated Heart Failure etiology determine one following : AST and/or ALT value exceed 3 X ULN and/or bilirubin &gt; 1.5 X ULN screen history hepatic encephalopathy , esophageal varix , portacaval shunt , diagnosis cirrhosis mean , evidence chronic Hepatitis B ( presence hepatitis B surface antigen production : positive HBsAg ) , chronic Hepatitis C infection ( presence Hepatitis C genetic replication : positive Hepatitis C viral RNA , base history and/or clinical finding , include laboratory result obtain screening period ) . *Significant uncorrected leave ventricular outflow obstruction , obstructive hypertrophic cardiomyopathy severe aortic stenosis ( i.e. , aortic valve area &lt; 1.0 cm2 mean gradient &gt; 50 mmHg prior current echocardiogram ) , severe mitral stenosis History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past year life expectancy le 1 year Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Serelaxin ,</keyword>
	<keyword>WHF ,</keyword>
	<keyword>Likert Scale ,</keyword>
	<keyword>RELAX-AHF-ASIA ,</keyword>
	<keyword>RLX030 ,</keyword>
	<keyword>AHF ,</keyword>
	<keyword>acute heart failure</keyword>
</DOC>